WVE

In December 2025, the stock surged by 147% following positive clinical data for WVE-007. In January 2026, Wave regained full rights to WVE-006 after GSK exited the program and outlined its 2026 priorities. In February 2026, Wave reported its Fourth Quarter and Full Year 2025 financial results, reiterating its cash runway into Q3 2028. In March 2026, the stock declined by approximately 49.6% after interim Phase 1 data for WVE-007. In April 2026, Wave announced a proposed redomiciliation to the United States and reported its First Quarter 2026 financial results, showcasing a significant revenue increase. In May 2026, Wave Life Sciences attracted positive attention following an analyst upgrade for a competitor, Korro Bio.